<DOC>
	<DOCNO>NCT00371709</DOCNO>
	<brief_summary>TAXUS ATLAS global , multi-center , single-arm , non-inferiority trial compare result patient treat TAXUS Liberté stent historical TAXUS Express control . The control group case-matched , blended population TAXUS Express patient TAXUS IV TAXUS V de novo clinical trial . The objective study evaluate clinical outcome TAXUS Liberté-SR stent de novo lesion ass non-inferiority TAXUS Liberté versus TAXUS Express . The TAXUS Liberté-SR stent hypothesize comparable safety efficacy TAXUS Express stent .</brief_summary>
	<brief_title>TAXUS ATLAS : TAXUS Liberté™-SR Stent Treatment de Novo Coronary Artery Lesions</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General 1 . Patient ≥18 year old . 2 . Eligible percutaneous coronary intervention ( PCI ) 3 . Documented stable angina pectoris unstable angina pectoris document ischemia document silent ischemia 4 . Left ventricular ejection fraction ( LVEF ) &gt; /=25 % 5 . Acceptable candidate coronary artery bypass grafting ( CABG ) 6 . Patient legal guardian understands study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform 7 . Willing comply specify followup evaluation Angiographic 1 . Only one lesion ( target lesion ) may treat study stent . However , one additional lesion nontarget vessel may treat index procedure commercially available bare metal stent , heparincoated stent TAXUS Express stent . 2 . Target lesion enrol treatment may compose multiple lesion ( 10mm diseased segment ) must completely cover one study stent . 3 . Target lesion locate within single native coronary artery 4 . Cumulative target lesion length ≥10 mm ≤28 mm ( visual estimate ) 5 . RVD ≥2.5 mm ≤4.0 mm ( visual estimate ) 6 . Target lesion diameter stenosis ≥50 % ( visual estimate ) 7 . Target lesion de novo ( i.e. , coronary lesion previously treat ) General 1 . Known hypersensitivity paclitaxel 2 . Any previous , concurrent plan treatment nonstudy antirestenotic drugcoated drugeluting coronary stent . 3 . Previous plan use study stent nonstudy stent ( i.e. , commercial stent ) treatment target vessel 4 . Previous plan treatment intravascular brachytherapy target vessel 5 . Planned CABG ≤9months postindex procedure 6 . MI within 72 hour prior index procedure creatine kinase ( CK ) &gt; 2x local laboratory 's ULN unless CKMB &lt; 2x ULN . 7 . Cerebrovascular Accident ( CVA ) within past 6 month 8 . Cardiogenic Shock 9 . Acute chronic renal dysfunction 10 . Contraindication ASA , clopidogrel ticlopidine 11 . Leukopenia 12 . Thrombocytopenia thrombocytosis 13 . Active peptic ulcer active gastrointestinal ( GI ) bleed 14 . Known allergy stainless steel 15 . Any prior true anaphylactic reaction contrast agent 16 . Patient currently , treat paclitaxel chemotherapeutic agent within 12months index procedure 17 . Anticipated treatment paclitaxel oral rapamycin period 9months index procedure 18 . Male female know intention procreate within 3 month index procedure 19 . Female childbearing potential positive pregnancy test within 7 day index procedure , lactating , intend become pregnant study . 20 . Life expectancy le 24months due medical condition 21 . Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study 22 . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study . Angiographic 1 . Left main coronary artery disease ( stenosis &gt; 50 % ) whether protect unprotected 2 . Target lesion ostial location ( within 3.0 mm vessel origin ) 3 . Target lesion and/or target vessel proximal target lesion moderately severely calcified visual estimate . 4 . Target lesion and/or target vessel proximal target lesion tortuous . 5 . Target lesion locate within distal &gt; 60 degree bend vessel 6 . Target lesion involve bifurcation side branch vessel &gt; 2.0 mm diameter . 7 . Target lesion totally occlude ( TIMI flow &lt; /= 1 ) , either baseline predilation 8 . Angiographic presence probable definite thrombus 9 . Pretreatment target vessel allow device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>